参考文献/References:
[1] HASSERJIAN R P,GERMING U,MALCOVATI L.Diagnosis and classification of myelodysplastic syndromes[J].Blood,2023,142(26):2247-2257.
[2] WHITELEY A E,PRICE T T,CANTELLI G,et al.Leukaemia:A model metastatic disease[J].Nat Rev Cancer,2021,21(7):461-475.
[3] CAPPELL K M,KOCHENDERFER J N.Long-term outcomes following CAR T cell therapy:What we know so far[J].Nat Rev Clin Oncol,2023,20(6):359-371.
[4] 张海燕,唐岚,廖春淑,等.急性白血病化疗后中性粒细胞缺乏合并感染患者临床特征及血清免疫因子检测临床意义[J].陕西医学杂志,2024,53(2):239-242,251.
[5] ZHANG X,ZHU L,ZHANG H,et al.CAR-T cell therapy in hematological malignancies:Current opportunities and challenges[J].Front Immunol,2022,13(927153):1-20.
[6] 刘明吉,朱惠芳.NKG2D受体-配体信号轴在肿瘤免疫治疗中的研究进展[J].中华肿瘤防治杂志,2023,30(20):1250-1256.
[7] LENARTIC M,JELENCIC V,ZAFIROVA B,et al.NKG2D promotes B1a cell development and protection against bacterial infection[J].J Immunol,2017,198(4):1531-1542.
[8] 张妍,刘爱国.NKG2D受体配体系统介导肿瘤免疫逃逸的研究进展[J].中国肿瘤,2020,29(8):602-607.
[9] 邓黎黎,张岩,张壮苗,等.沙利度胺对白血病细胞NKG2D配体表达及NK细胞杀伤敏感性的影响[J].临床与病理杂志,2022,42(1):9-14.
[10] PACZULLA A M,ROTHFELDER K,RAFFEL S,et al.Publisher correction:Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion[J].Nature,2019,572(7768):254-259.
[11] BARAGAÑO-RANEROS A,MARTÍN-PALANCO V,FERNANDEZ A F,et al.Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia[J].Genes Immun,2015,16(1):71-82.
[12] LAZAROVA M,STEINLE A.The NKG2D axis:An emerging target in cancer immunotherapy[J].Expert Opin Ther Targets,2019,23(4):281-294.
[13] LAZAROVA M,STEINLE A.Impairment of NKG2D-mediated tumor immunity by TGF-β[J].Front Immunol,2019,10:2689.
[14] HUANG X,MO Q,FU T,et al.STAT1 is associated with NK cell dysfunction by downregulating NKG2D transcription in chronic HBV-infected patients[J].Immunobiology,2022,227(6):152272.
[15] LIU H,WANG S,XIN J,et al.Role of NKG2D and its ligands in cancer immunotherapy[J].Am J Cancer Res,2019,9(10):2064-2078.
[16] SCHMIEDEL D,MANDELBOIM O.NKG2D ligands-critical targets for cancer immune escape and therapy[J].Front Immunol,2018,9(2040):1-10.
[17] WU Z,ZHANG H,WU M,et al.Targeting the NKG2D/NKG2D-L axis in acute myeloid leukemia[J].Biomed Pharmacother,2021,137(5973):111299.
[18] PAZINA T,JAMES A M,COLBY K B,et al.Enhanced SLAMF7 homotypic interactions by elotuzumab improves NK cell killing of multiple myeloma[J].Cancer Immunology Research,2019,7(10):1633-1646.
[19] ANTOSOVA Z,PODZIMKOVA N,TOMALA J,et al.SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity[J].Front Immunol,2022,13:989895.
[20] ZHU Z C,BAI Y,LU X Z,et al.Effects and mechanism of PARP inhibitor olaparib on the expression of NKG2D ligands in HL-60 cells[J].Zhongguo Shi Yan Xue Ye Xue Za Zhi,2020,28(6):1826-1830.
[21] 雷秦,王梦昌,王娟.苦参碱对NK细胞杀伤HL60细胞的影响及其机制研究[J].陕西医学杂志,2015,44(10):1275-1277.
[22] STOJANOVIC A,CORREIA M P,CERWENKA A.The NKG2D/NKG2DL axis in the crosstalk between lymphoid and myeloid cells in health and disease[J].Front Immunol,2018,9:827.
[23] WU H Y,LI K X,PAN W Y,et al.Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway[J].Int Immunopharmacol,2022,104:108497.
[24] TABARSA M,DABAGHIAN E H,YOU S,et al.The activation of NF-κB and MAPKs signaling pathways of RAW264.7 murine macrophages and natural killer cells by fucoidan from nizamuddinia zanardinii[J].Int J Biol Macromol,2020,148:56-67.
[25] MILJKOVIC M D,DUBOIS S P,MÜLLER J R,et al.Interleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies[J].Blood Adv,2023,7(3):384-394.
[26] 王海南,孙艳舫,杨淑莲,等.益气养阴方治疗骨髓抑制期气阴两虚型急性白血病临床研究[J].陕西中医,2022,43(4):465-468.
[27] 王雪梅,汤久慧,王茂生,等.参芪杀白汤为主联合化疗治疗急性白血病合并脾周围炎临床研究[J].陕西中医,2020,41(2):202-205.
[28] KUMAR S,TOMAR M S,ACHARYA A.Chelerythrine delayed tumor growth and increased survival duration of dalton's lymphoma bearing BALB/c H(2d)mice by activation of NK cells in vivo[J].J Cancer Res Ther,2015,11(4):904-910.
[29] XING L,WANG S,LIU J,et al.BCMA-specific ADC MEDI2228 and daratumumab induce synergistic myeloma cytotoxicity via IFN-driven immune responses and enhanced CD38 expression[J].Clin Cancer Res,2021,27(19):5376-5388.
[30] WANG Y,LI H,XU W,et al.BCMA-targeting bispecific antibody that simultaneously stimulates NKG2D-enhanced efficacy against multiple myeloma[J].J Immunother,2020,43(6):175-188.
[31] 王艳婕,曹威,周彦生,等.NKG2D配体在 NK细胞杀伤三氧化二砷诱导的KG1a细胞中的作用[J].中国免疫学杂志,2021,37(3):268-272.
[32] FUERTES M B,DOMAICA C I,ZWIRNER N W.Leveraging NKG2D Ligands in immuno-oncology[J].Front Immunol,2021,12:713158.
[33] TANG L,WU J,LI C G,et al.Characterization of immune dysfunction and identification of prognostic immune-related risk factors in acute myeloid leukemia[J].Clin Cancer Res,2020,26(7):1763-1772.